Physician profile
Scott E Wilson
NPI 1346624459
$2,254.85
in general payments reported to CMS, 2019-2025
21 companies · $48.06 in 2025
The $48.06 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $525 · 2022: $918 · 2023: $696 · 2024: $67.32 · 2025: $48.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $811.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $455.24 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $202.94 | 2021-2023 | Farxiga, Breztri |
| Abbvie INC. | $192.35 | 2021-2023 | |
| Lilly USA, LLC | $176.62 | 2021-2023 | Emgality, Jardiance, Mounjaro |
| Novo Nordisk INC | $173.74 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $164.80 | 2022 | |
| Janssen Pharmaceuticals, INC | $152.02 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.79 | 2021-2023 | |
| Amgen INC. | $142.93 | 2021-2024 | Evenity, Prolia, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $85.57 | 2021-2023 | Trintellix |
| Astellas Pharma US INC | $59.75 | 2021-2023 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.74 | 2022 | |
| Sanofi Pasteur INC. | $40.90 | 2022 | |
| Pfizer INC. | $40.26 | 2021-2022 | |
| Exact Sciences Corporation | $36.42 | 2023 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $32.44 | 2021 | |
| Abbott Laboratories | $22.30 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $19.17 | 2021 | |
| Merck Sharp & Dohme LLC | $18.50 | 2022 | |
| Aimmune Therapeutics, INC. | $18.47 | 2025 | Zenpep |
| Daiichi Sankyo INC. | $15.90 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.